公开(公告)号：US20170051286A1

公开(公告)日：2017-02-23

申请号：US15308235

申请日：2015-05-01

Applicant: Larry J. Smith

Inventor： Larry J. Smith

IPC: C12N15/113 ,  C12N15/11

CPC classification number: C12N15/113 ,  C07H21/04 ,  C12N15/111 ,  C12N2310/14 ,  C12N2310/141 ,  C12N2310/315 ,  C12N2310/32 ,  C12N2310/321 ,  C12N2310/344 ,  C12N2310/346 ,  C12N2320/50

Abstract: Compositions and methods for down modulating expression of target nucleic acids using a single strand oligoribonucleotide siRNA compound are disclosed.

Abstract translation: 公开了使用单链寡核糖核苷酸siRNA化合物降低靶核酸表达的组合物和方法。

公开(公告)号：US20120156138A1

公开(公告)日：2012-06-21

申请号：US13264482

申请日：2009-04-14

Applicant: Larry J. Smith

Inventor： Larry J. Smith

IPC: A61K49/00 ,  A61K9/127 ,  A61K38/00 ,  A61K38/08 ,  A61K38/10 ,  A61K38/16 ,  C12N5/02 ,  A61P35/00 ,  A61P31/14 ,  A61P25/28 ,  A61P9/10 ,  A61P37/02 ,  A61P3/10 ,  A61P9/00 ,  A61P27/02 ,  A61P25/00 ,  A61P25/16 ,  A61P17/06 ,  A61P11/06 ,  A61P19/02 ,  A61P31/12 ,  A61P7/06 ,  A61P31/18 ,  A61P35/02 ,  A61K31/7088 ,  B82Y5/00

CPC classification number: C12Q1/6886 ,  C12Q2600/158

Abstract: The present invention provides a variety of nucleic acid based therapeutics and methods of use thereof which are effective to beneficially reprogram diseased cells such that they exhibit more desirable phenotypes. Also provided are compositions and methods to reprogram normal cells for medical and commercial purposes.

Abstract translation: 本发明提供了各种基于核酸的治疗剂及其使用方法，其有效地有益地重新编程患病细胞，使得它们表现出更期望的表型。 还提供了用于重新编程正常细胞用于医疗和商业目的的组合物和方法。

公开(公告)号：US07960364B2

公开(公告)日：2011-06-14

申请号：US12636452

申请日：2009-12-11

Applicant: Dayton T. Reardan ,  Larry J. Smith ,  Robert E. Klem

Inventor： Dayton T. Reardan ,  Larry J. Smith ,  Robert E. Klem

IPC: A01N43/04 ,  A01N61/00 ,  C12N15/63 ,  C07H21/02 ,  C07H21/04

CPC classification number: C07K16/1063 ,  A61K31/136 ,  A61K31/70 ,  A61K31/7088 ,  A61K31/713 ,  A61K39/39558 ,  A61K39/39575 ,  A61K2039/505 ,  C07K16/32 ,  C07K2317/34 ,  C12N9/0002 ,  A61K2300/00

Abstract: Covalently reactive antigen analogs are disclosed herein. The antigens of the invention may be used to stimulate production of catalytic antibodies specific for predetermined antigens associated with particular medical disorders. The antigen analogs may also be used to permanently inactivate endogenously produced catalytic antibodies produced in certain autoimmune diseases as well as in certain lymphoproliferative disorders. Also provided are methods for modulating the efficacy of nucleic acid based therapeutics.

Abstract translation: 本文公开了共价反应性抗原类似物。 本发明的抗原可用于刺激对与特定医学病症相关的预定抗原特异性的催化抗体的产生。 抗原类似物也可用于永久灭活在某些自身免疫性疾病以及某些淋巴组织增生性疾病中产生的内源性产生的催化抗体。 还提供了用于调节基于核酸的治疗剂的功效的方法。

公开(公告)号：US20100172966A1

公开(公告)日：2010-07-08

申请号：US12658042

申请日：2010-02-01

Applicant: Larry J. Smith

Inventor： Larry J. Smith

IPC: A61K9/127 ,  A61K31/713 ,  A61K38/19 ,  A61K48/00 ,  A61P31/18 ,  A61P31/16 ,  A61P31/22 ,  A61P25/28 ,  A61P19/02 ,  A61P37/00 ,  A61P9/10 ,  C12N5/10 ,  C12N5/078 ,  C12N5/071 ,  C12N5/074 ,  C12N5/077

CPC classification number: C12Q1/6886 ,  C12N15/113 ,  C12N15/1135 ,  C12N2310/11 ,  C12Q2600/106

Abstract: Compositions and methods useful for the treatment of aberrant programming diseases, particularly those associated with aberrant apoptosis are disclosed

Abstract translation: 公开了用于治疗异常程序性疾病，特别是与异常凋亡相关的疾病的组合物和方法

公开(公告)号：US5248671A

公开(公告)日：1993-09-28

申请号：US805210

申请日：1991-12-09

Applicant: Larry J. Smith

Inventor： Larry J. Smith

IPC: C07H21/00 ,  C12N15/113

CPC classification number: A61K31/70 ,  C07H21/00 ,  C12N15/1135

Abstract: The present invention provides methods useful in autologous bone marrow transplantation and cancer therapy. According to one aspect of the invention, bone marrow cells from a patient having cancer are treated with selected antisense oligonucleotides in order to deplete the bone marrow of malignant cells prior to infusion back into the bone marrow donor. In a separate embodiment, selected antisense oligonucleotides are administered systemically for anticancer therapy.

Abstract translation: 本发明提供了在自体骨髓移植和癌症治疗中有用的方法。 根据本发明的一个方面，来自患有癌症的患者的骨髓细胞用选择的反义寡核苷酸处理，以在输回到骨髓供体之前消耗恶性细胞的骨髓。 在单独的实施方案中，选择的反义寡核苷酸全身用于抗癌治疗。

公开(公告)号：US20230220393A1

公开(公告)日：2023-07-13

申请号：US18155730

申请日：2023-01-17

Applicant: Larry J. Smith

Inventor： Larry J. Smith

IPC: C12N15/113 ,  C07H21/04 ,  C12N15/11 ,  C07H21/02

CPC classification number: C12N15/113 ,  C07H21/04 ,  C12N15/111 ,  C07H21/02 ,  C12N2320/50 ,  C12N2310/315 ,  C12N2310/322 ,  C12N2310/321 ,  C12N2310/14 ,  C12N2310/346 ,  C12N2320/51 ,  C12N2310/344 ,  C12N2310/141 ,  C12N2310/32

Abstract: Compositions and methods for modulating expression of target nucleic acids using a single strand oligoribonucleotide ss-siRNA compound are disclosed.

公开(公告)号：US20220290150A1

公开(公告)日：2022-09-15

申请号：US17752530

申请日：2022-05-24

Applicant: Larry J. Smith

Inventor： Larry J. Smith

IPC: C12N15/113 ,  A61K31/713 ,  A61K31/7125 ,  A61K31/712

Abstract: Compositions and methods for down modulating target gene expression which RNA interference, as well as methods for administering said compositions are disclosed. The method comprises administering a first oligonucleotide strand to a cell, incubating the cells for a time period suitable for uptake of the first oligo nucleotide strand prior to administration of a second oligonucleotide strand, wherein the first strand and the second strand form an intracellular duplex which is effective to catalyze degradation of gene target mRNA or inhibit translation of said mRNA.

公开(公告)号：US20150025122A1

公开(公告)日：2015-01-22

申请号：US14148191

申请日：2014-01-06

Applicant: Larry J. Smith

Inventor： Larry J. Smith

IPC: A61K31/713 ,  A61K31/712 ,  C12N15/113 ,  A61K31/7125

CPC classification number: C12N15/1135 ,  A61K31/712 ,  A61K31/7125 ,  A61K31/713 ,  C12N15/113 ,  C12N15/1136 ,  C12N15/1137 ,  C12N15/1138 ,  C12N2310/11 ,  C12N2310/14 ,  C12N2310/31 ,  C12N2310/315 ,  C12N2310/321 ,  C12N2310/322 ,  C12N2310/3513 ,  C12N2310/51 ,  C12N2320/31 ,  C12N2320/35 ,  C12N2320/51 ,  C12N2310/3521 ,  A61K2300/00

Abstract: Compositions and methods for down modulating target gene expression with RNA interference, as well as methods for administering said compositions are disclosed. The method comprises administering a first strand to a cell, incubating the cell for a time period suitable for uptake of the first oligo prior to administering a second strand, wherein the first strand and said second strand form an intracellular duplex which is effective to catalyze degradation of gene target mRNA or inhibit translation of said mRNA.

Abstract translation: 公开了用RNA干扰降低靶基因表达的组合物和方法，以及用于施用所述组合物的方法。 该方法包括向细胞施用第一链，在施用第二链之前将细胞孵育适合摄取第一寡核苷酸的时间段，其中第一链和第二链形成有效催化降解的细胞内双链体 的基因靶mRNA或抑制所述mRNA的翻译。

公开(公告)号：US20150010502A1

公开(公告)日：2015-01-08

申请号：US14232452

申请日：2012-07-12

Applicant: Larry J. Smith

Inventor： Larry J. Smith

IPC: C12N15/113 ,  A61K45/06 ,  A61K31/713

CPC classification number: C12N15/1135 ,  A61K31/7088 ,  A61K31/713 ,  A61K45/06 ,  C12N15/113 ,  C12N2310/11 ,  C12N2310/14 ,  C12N2310/315 ,  C12N2310/3231 ,  C12N2310/3233 ,  C12N2310/331 ,  C12N2310/332 ,  C12N2310/3513 ,  C12N2320/30 ,  C12N2310/321 ,  C12N2310/3521 ,  C12N2310/322 ,  C12N2310/3533

Abstract: Compositions and methods for inhibition of p53 and clusterin expression in target cells for the treatment of disease are disclosed.

Abstract translation: 公开了用于抑制靶细胞中p53和簇蛋白表达的组合物和方法用于治疗疾病。

公开(公告)号：US07517644B1

公开(公告)日：2009-04-14

申请号：US08472801

申请日：1995-06-07

Applicant: Larry J. Smith

Inventor： Larry J. Smith

IPC: C07H21/02 ,  A61K31/70 ,  C12Q1/68

CPC classification number: C12Q1/6886 ,  C12N15/113 ,  C12N15/1135 ,  C12N2310/11 ,  C12Q2600/106

Abstract: The present invention provides methods and compositions useful in treating certain diseases herein termed “Aberrant Programming Diseases,” including cancer and AIDS. According to one aspect of the invention, there is provided a method for treating an individual having an Aberrant Programming disease comprising administering to said individual an effective amount of a composition selected from the group consisting of an expression vector, a double stranded oligodeoxynucleotide, and an antisense oligodeoxynucleotide; said composition capable of regulating expression of a transcriptional regulator, said transcriptional regulator being expressed by the Aberrant Programming cells and further characterized by exhibiting a therapeutically useful change in said cell behavior in the Reprogramming Test. In a separate embodiment new antisense oligodeoxynucleotides are provided.

Abstract translation: 本发明提供了可用于治疗本文称为“异常程序设计疾病”（包括癌症和AIDS）的某些疾病的方法和组合物。 根据本发明的一个方面，提供了一种用于治疗患有异常规划疾病的个体的方法，包括向所述个体施用有效量的选自以下的组合物：表达载体，双链寡脱氧核苷酸和 反义寡脱氧核苷酸; 所述组合物能够调节转录调节物的表达，所述转录调节子由异常编程细胞表达，并进一步表征为在重编程测试中表现出所述细胞行为的治疗上有用的变化。 在单独的实施方案中，提供了新的反义寡脱氧核苷酸。